RecruitingNCT07148323

HemoSphere Alta Study

HemoSphere Alta Clinical Development Study


Sponsor

Edwards Lifesciences

Enrollment

100 participants

Start Date

Oct 14, 2025

Study Type

OBSERVATIONAL

Conditions

Summary

A prospective, non-randomized single arm study using the HemoSphere Alta Advanced Monitoring Platform and associated devices in adult subjects. Data collected from enrolled study subjects will be used for continual device development purposes.


Eligibility

Min Age: 18 Years

Inclusion Criteria12

  • Signed informed consent
  • Age ≥ 18 years
  • Planned monitoring with a pulmonary artery catheter
  • Patient scheduled to undergo cardiac or liver transplant surgery lasting \> 2 hours
  • Additional criteria for Sub-Cohort A (RVF)
  • Possible Right Ventricular Dysfunction/Failure based on pre-operative assessment of previous Transthoracic Echocardiogram (TTE)
  • Planned Transesophageal Echocardiogram (TEE) assessment during the operative procedure
  • Additional criteria for Sub-Cohort B (CAI)
  • Age ≥ 45 years
  • Planned cardiac surgery with Cardiopulmonary Bypass (CPB)
  • Ability to place ForeSight IQ and Acumen IQ sensors during the operative monitoring period
  • High risk for cerebral vascular disease, defined as: a history of hypertension, pulse pressure \> 60 mmHg, diabetes, stroke, transient ischemic attack, carotid bruit, tobacco smoking, or peripheral vascular disease

Exclusion Criteria8

  • Inability to provide informed consent
  • Pregnancy as confirmed per EMR
  • Patients deemed not suitable for the study at the discretion of the Investigator
  • Participation in another study that clinically interferes with the current study
  • Presence of left bundle branch block
  • Presence of current/recurrent sepsis
  • Presence of hypercoagulability, as identified in the patient's past medical history and preoperative evaluation
  • Structural abnormality, including congenital heart defects, of the right ventricle

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DEVICEHemoSphere Alta Monitor, Swan-Ganz IQ pulmonary arterial catheter, ForeSight IQ Large sensor, and Acumen IQ sensor

Subjects with planned monitoring with a pulmonary artery catheter in the operating room, will be monitored with the above listed devices.


Locations(1)

University of Rochester Medical Center

Rochester, New York, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07148323


Related Trials